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Key points 
 The ClinGen MM-VCEP has specified RUNX1-specific curation rules to address gene 
function, gene-specific domains, and phenotypic criteria. 
 RUNX1-specific criteria resulted in a reduction of CONF variants and VUS by 33%, 
emphasizing the need for expert variant curation. 
 4 
Abstract 
 
Standardized variant curation is essential for clinical care recommendations for patients with 
inherited disorders. Clinical Genome Resource (ClinGen) variant curation expert panels are 
developing disease-associated gene specifications using the 2015 American College of Medical 
Genetics and Genomics (ACMG) and Association for Molecular Pathology (AMP) guidelines to 
reduce curation discrepancies. The ClinGen Myeloid Malignancy Variant Curation Expert Panel 
(MM-VCEP) was created collaboratively between the American Society of Hematology (ASH) 
and ClinGen to perform gene and disease-specific modifications for inherited myeloid 
malignancies. The MM-VCEP began optimizing ACMG/AMP rules for RUNX1, since many 
germline variants have been described in patients with familial platelet disorder with 
predisposition to acute myeloid leukemia (FPD/AML), characterized by thrombocytopenia, 
platelet functional/ultrastructural defects, and a predisposition to hematologic malignancies. The 
28 ACMG/AMP codes were tailored for RUNX1 variants by modifying gene/disease 
specifications, incorporating strength adjustments of existing rules, or both.  Key specifications 
included calculation of minor allele frequency thresholds, formulating a semiquantitative 
approach to counting multiple independent variant occurrences, identification of functional 
domains and mutational hot spots, establishing functional assay thresholds, and characterizing 
phenotype-specific guidelines. Preliminary rules were tested using a pilot set of 52 variants, 
among which 50 were previously classified as benign/likely benign (BEN/LBEN), 
pathogenic/likely pathogenic (PATH/LPATH), variant of unknown significance (VUS), or 
conflicting interpretations (CONF) in ClinVar. The application of RUNX1-specific criteria resulted 
in a reduction of CONF variants and VUS by 33%, emphasizing the benefit of gene-specific 
criteria and sharing internal laboratory data.  
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Introduction 
 
In 2015, the American College of Medical Genetics and Genomics (ACMG) and the 
Association for Molecular Pathology (AMP) released a landmark document providing guidance 
on variant classification, which is now adopted by many international diagnostic laboratories. It 
was designed to have universal applicability to all Mendelian disorders, using several types of 
weighted and categorized evidence, and therefore requires significant expertise as well as 
gene- and disease-specific knowledge to be correctly applied.1 Variable application of functional 
and domain-related evidence and inconsistent interpretation and use of the ACMG/AMP criteria 
are key contributors to incorrect classifications of variants and significant discrepancies among 
laboratories highlight the utility of expert guidance.2–4 A few studies have proposed approaches 
to one or more aspects of variant interpretation, such as quantitative criteria for co-segregation, 
use of population databases, adaptation of minor allele frequency (MAF), classes of evidence, 
and gene-level implications.2–8 However, due to the unique characteristics of every gene and its 
disease correlates, along with the variability in the application of classification criteria and 
evidence interpretation, there is still a lack of comprehensive guidance for variant interpretation. 
This need for expert involvement and gene-specific guidance has been addressed by 
the National Institutes of Health funded Clinical Genome Resource (ClinGen, 
https://clinicalgenome.org), which serves as a body for managing and centralizing clinically 
relevant genomic knowledge, providing guidance and tools for defining the clinical validity of 
gene and variant contribution to disease. Several working groups and expert panels were 
created within ClinGen, including gene and disease-specific Variant Curation Expert Panels 
(VCEPs).9,10 Moreover, the ClinGen Sequence Variant Interpretation Working Group (SVI, 
https://clinicalgenome.org/working-groups/sequence-variant-interpretation/) aims to provide 
general recommendations for the refinement and evolution of the ACMG/AMP guidelines then to 
be specialized further by the gene-specific VCEP.  
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The publicly available ClinVar database (https://www.ncbi.nlm.nih.gov/clinvar/), launched 
in 2013, serves as a valuable centralized resource for documenting the clinical significance of 
genetic variants submitted by clinical and research laboratories and databases such as OMIM 
and GeneReviews.11 ClinVar utilizes the ACMG-recommended five-level scoring system to 
indicate the level of evidence supporting the assertion of clinical significance of a variant. 
Human variant data curated by ClinGen expert panels are submitted to ClinVar with a three-star 
status (reviewed by expert panel) including a designation that the ClinGen VCEP process has 
been recognized by the Food and Drug Administration. 
The general work-flow of a VCEP is to define its leadership/membership and scope of 
focus as well as conflicts of interest.9 Once approved, this group develops disease-specific 
variant classification rules, based on curation of gene-specific features, published literature, and 
evidence thresholds that are consistent with gene-disease associations.  ACMG and AMP have 
defined 28 codes that address specific evidence, including population data, segregation data, 
functional data, computational predictions, and allelic data.3 Each code is weighted according to 
the strength of the evidence: stand-alone, very strong, strong, moderate, or supporting.  Codes 
are also designated as defining the direction of clinical significance:  benign or pathogenic.  
These evidence codes applied to variants are then combined to arrive at a single designation of 
clinical significance: pathogenic (PATH), likely pathogenic (LPATH), variant of uncertain 
significance (VUS), likely benign (LBEN), or benign (BEN).  Once preliminary rules are 
specified, they are pilot tested on a collection of variants with existing assertions of clinical 
significance, and based on the results of this preliminary testing, the VCEP may adjust some of 
its rules to optimize variant classification.  Once final rules have been approved, they are 
published and implemented, with VCEP-curated assertions disseminated via the ClinVar 
database. 
A Myeloid Malignancy VCEP, hereafter referred to as MM-VCEP, was formed in 2018, 
as a collaboration between the American Society of Hematology (ASH) and ClinGen. The MM-
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VCEP began adapting the ACMG/AMP framework for RUNX1 variant classification, because as 
the first germline predisposition syndrome identified for myeloid malignancies, there were many 
variants already deposited in the ClinVar repository.  Germline pathogenic variants in RUNX1, 
first described in 1999, cause dominantly inherited familial platelet disorder with predisposition 
to acute myeloid leukemia (FPD/AML), characterized by mild to moderate thrombocytopenia, 
functional and ultrastructural platelet defects, and a predisposition to myelodysplastic syndrome 
(MDS) and acute myeloid leukemia (AML) and less frequently to T-cell acute lymphoblastic 
leukemia (T-ALL).12–14 In 2016, the revision of the World Health Organization (WHO) 
classification of myeloid neoplasms and acute leukemia included myeloid malignancies arising 
from germline pathogenic variants in ANKRD26, ETV6, and RUNX1 in a new category defined 
as ‘Myeloid neoplasms with germline predisposition and pre-existing platelet disorder’.15 
Reported inherited and de novo RUNX1 variants include missense, nonsense, and splice site 
single-nucleotide variants (SNVs), small in- or out-of-frame insertions and deletions (indels), as 
well as copy number variants (CNVs), such as intragenic or whole gene-deletions.16–18 The 
prevalence of pathogenic RUNX1 germline variants is unknown, but presumed to be rare. The 
disease shows high penetrance with variable expressivity and genotype/phenotype correlation, 
and the life-time risk of hematologic malignancies is approximately 44%, with an average age of 
onset at 33 years.19–21 More than half of germline RUNX1 variants are reported in single 
probands/families,13 leading to a high allelic heterogeneity that restricts the collection of data 
from segregation analyses and functional analyses across several affected families. Individuals 
with a hematologic malignancy are often candidates for hematopoietic stem cell transplantation. 
The identification of patients with a pathogenic germline variant in RUNX1 and its correct 
classification of the variant are imperative to the selection of potential related donors, among 
other clinical implications.22–26  
 Here, we present the RUNX1-specific guidelines generated by the MM-VCEP.  The MM-
VCEP adapted the ACMG/AMP framework for RUNX1 variant classification with the aim of 
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improving consistency in variant classification and curating RUNX1 variants for three-star 
submission to ClinVar. We have used multiple lines of evidence, showing the rationale and data 
supporting each criterion’s modification, and the results from pilot testing the criteria on variants 
with BEN/LBEN, PATH/LPATH, VUS, and conflicting (CONF) ClinVar assertions. The 
application of rules for RUNX1 variant curation will serve as a model for the curation of variants 
in other genes that also cause inherited myeloid hematologic malignancies, such as ANKRD26, 
ETV6, DDX41, and GATA2.  The ClinGen’s website contains the MM-VCEP variant 
classification recommendations and any subsequent modifications to these codes over time 
(https://www.clinicalgenome.org/affiliation/50034). 
 
Methods 
ClinGen Myeloid Malignancy Variant Curation Expert Panel 
The MM-VCEP is sponsored by ASH through its partnership with ClinGen and is 
described at https://clinicalgenome.org/affiliation/50034/. The MM-VCEP team is comprised of 
34 professionals with expertise in key domains and includes clinical geneticists, genetic 
counselors, hematologists with professional training in genetics, laboratory and research 
scientists, and variant curation experts. Additional emphasis was placed on global 
representation, with 23 participating international institutions in six countries: Australia, France, 
Italy, Sweden, the United Kingdom, and the United States. The MM-VCEP meets regularly via 
bi-weekly teleconferences and corresponds via email on a regular basis. Approval of MM-VCEP 
is overseen by ClinGen and consists of four steps: (1) defining the group/members and scope of 
the VCEP, (2) developing gene/disease-specific classification rules, (3) optimization of rules 
using pilot variants, and (4) MM-VCEP approval by ClinGen, implementation of rules in the 
ClinGen Variant Curation Interface (VCI) and submission of curated variants to the ClinVar 
database. For step two, members were divided into three subgroups that focused on the 
modification of functional/computational/splicing criteria (Team F), population/phenotypic criteria 
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(Team P), and segregation/allelic/de novo criteria (Team S). All members disclosed potential 
conflicts of interest as required by ClinGen.  
ACMG/AMP specifications for RUNX1 
MM-VCEP members proposed and discussed changes to the existing ACMG/AMP 
classifications for RUNX1 germline variants and arrived at consensus decisions via 
teleconference calls and email. Criteria modifications included gene or disease-specific 
modifications, strength-level adjustments, general recommendations, and certain criteria being 
deemed ‘not applicable’. Publicly available databases, predictive software and published data 
obtained from relevant manuscripts were used for criteria specifications. For BA1/BS1 RUNX1 
specific population MAF, calculations were made assuming Hardy-Weinberg equilibrium using 
the recently published Whiffin/Ware online calculator.6 Additional efforts included identification of 
key functional domains and mutational hot spots within RUNX1, defining informative functional 
assays, and characterizing phenotypic criteria. Recommendations for using ACMG/AMP criteria 
from the ClinGen’s SVI working group were also incorporated.27–29 Preliminary and final 
ACMG/AMP specifications required complete consensus of the MM-VCEP. 
Pilot variants  
 All pilot variants are annotated using RefSeq IDs NM_001754.4 and NC_000021.9 
(GRCh38/hg38). Variants submitted to ClinVar by a variety of clinical laboratories were 
prioritized for classification. Preliminary rules were refined by interpreting a set of 52 RUNX1 
variants, which were selected to represent the spectrum of variants in RUNX1, covering various 
types of SNVs such as missense, nonsense, splice site, synonymous and intronic variants, 
indels such as in-frame duplications and out-of-frame deletions, and CNVs such as intragenic 
deletions. Similarly, the pilot variants covered a diverse range of classifications in ClinVar 
including discrepant assertions (twelve BEN/LBEN, fourteen VUS, twenty PATH/LPATH, four 
CONF, two with no ClinVar assertions). The variant classification and rules applied were 
reviewed on conference calls to resolve discrepancies and reach consensus. Basic information 
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regarding individual phenotypes and segregation with disease was obtained from the literature 
and ClinVar submitters. Statistical approaches for calculations of PS4 are available in the 
Supplementary Methods.  Further optimization of rules was performed, and a discussion with 
the entire MM-VCEP was triggered whenever members disagreed or raised concerns regarding 
the applicability of a given rule. Curators utilized ClinGen’s VCI (VCI, 
https://curation.clinicalgenome.org) to assess and document the applicable rules for each 
variant. Once the MM-VCEP was approved, the classified RUNX1 variants with the adapted 
evidence code framework applied to the variants were submitted to ClinVar and were 
designated with a 3-star evidence code and FDA recognition flag.  The first 52 RUNX1 variant 
curations are now available in ClinVar and can be accessed at: 
https://www.ncbi.nlm.nih.gov/clinvar/submitters/507107/ 
 
Results 
Summary of rule specifications 
The final MM-VCEP ACMG/AMP specifications for RUNX1 were approved by ClinGen 
and are outlined in Table 1. Six out of the original 28 ACMG/AMP criteria had general 
recommendations on the application of the rule (PM2, PP3, BS4, BP2, BP4, BP7), two required 
gene- or disease-based specifications (BA1, BS1), and two rules were adjusted in their level of 
strength (PS1, PM5). Both gene- or disease-based and strength-level specifications were made 
to nine rules (PVS1, PS2, PS3, PS4, PM1, PM4, PM6, PP1, BS3). Five rules required 
exceptions for combinations with other rules (PS2, PS3, PM5, PM6, PP3), and nine rules were 
deemed not applicable (PM3, PP2, PP4, PP5, BS2, BP1, BP3, BP5, BP6). One change to the 
ACMG/AMP combination of criteria for classification of clinical significance was made in the 
case of BS1 which can be used as a stand-alone criterion for LBEN classification in the absence 
of any supporting pathogenic evidence. The following section highlights the approaches and 
rationale behind key specifications such as phenotypic criteria, MAF thresholds and validity of 
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functional assays. Of note, germline material for FPD/AML patients or patients with suspected 
inherited hematologic malignancies cannot include blood or bone marrow from these patients 
since this is the affected tissue harboring somatic mutations. We recommend using cultured 
skin fibroblasts as the gold standard, or alternatively DNA from hair roots or cultured 
mesenchymal stromal cells.19,25   
 
Phenotypic criteria for FPD/AML 
FPD/AML is characterized by mild to moderate thrombocytopenia, platelet functional 
and/or ultrastructural defects, and a predisposition to hematologic malignancies, most often 
AML and MDS, and less frequently T-ALL (Table 2). The penetrance is high; however, not all 
individuals carrying the pathogenic variant display the FPD/AML phenotype. Thrombocytopenia 
is the most common clinical presentation, followed by hematologic malignancies in 
approximately 44% of these patients.19–21 The MM-VCEP defined that in order to fit the 
FPD/AML phenotype, the patient must show at least one of the following phenotypic criteria: (1) 
mild to moderate thrombocytopenia with normal platelet size and volume in the absence of other 
causative factors such as autoimmune (e.g. antibodies against platelet surface antigens) or 
drug-related thrombocytopenia;30 (2) platelet ultrastructural and/or functional defects, including 
platelet alpha31 or dense granule secretion defects30,32,33 or impaired platelet aggregation – 
particularly in response to collagen and epinephrine;34,35 (3) diagnosis of a hematologic 
malignancy, most commonly affecting the myeloid lineage causing AML or MDS, less frequently 
involving the lymphoid lineage and manifesting as T-ALL.26,30,36,37 There are rare case reports of 
patients with germline RUNX1 variants and mixed myeloproliferative syndromes/MDS such as 
chronic myelomonocytic leukemia,26,38 as well as case reports of patients with B-ALL39 and 
hairy-cell leukemia.40 
Population data (BA1, BS1, PM2, PS4, PS4_moderate, PS4_supporting, BP2) 
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FPD/AML is a rare disorder. The prevalence of the disease-associated RUNX1 variants 
is unknown, with an estimated 5,515 families worldwide based on a population incidence 
generated from a survey of centers with FPD/AML patients (personal communication) which is 
likely an underestimate of the true prevalence. Among the three phenotypic features seen in 
individuals with germline RUNX1 variants (Table 2), thrombocytopenia is the most common. We 
conservatively estimated the prevalence of thrombocytopenia for use in the BA1/BS1 
calculations. Most clinical laboratories establish their reference values for platelet counts by 
measuring samples from at least 120 healthy individuals and identifying the most outlying 5% of 
observed values. Most often, these outlying observations are split evenly between the ends of 
the test result distribution in the reference population, 2.5% at each end of the distribution, 
resulting in a two-sided reference interval.41 Using this approach, the prevalence of 
thrombocytopenia can be defined as 1 in 40. The penetrance in families with RUNX1 germline 
variant is high to near-complete with 85% being the lowest penetrance reported to date (13,19–
21,unpublished internal data). So far, no founder variants in RUNX1 have been reported. De 
novo variants are rare, but have been described.16–18 The MM-VCEP modified BA1 using these 
conservative assumptions and corresponding values to account for the unknown prevalence 
and disease contribution of RUNX1. In order to obtain a RUNX1-specific population MAF 
threshold for BA1, we utilized the Whiffin/Ware calculator6 
(http://cardiodb.org/allelefrequencyapp/) with a prevalence of 1 in 40, a conservative 
unascertained penetrance estimate of 85%, an allelic heterogeneity of 100% and a maximum 
genetic heterogeneity of 10%. The MM-VCEP also adopted the SVI recommendation that the 
variant be present in any general continental population dataset with a minimum number of 
2,000 alleles and the variant is present in ≥ 5 alleles.42 A 95% confidence interval was used to 
develop the thresholds. The threshold developed for application of BA1 as a stand-alone 
criterion is a MAF equal to or higher than 0.0015 (0.15%). For BS1, a maximum genetic 
heterogeneity contribution of 1% (one magnitude lower) was used, which led to a range of 
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0.00015 (0.015%) up to 0.0015 (0.15%) for application of BS1. Since we have used 
conservative values for the calculation, we allow a variant to reach a LBEN classification based 
on BS1 alone if there is no contradictory evidence supporting pathogenicity (as outlined in a 
recent SVI revision).29 For this work, the gnomAD population database was mostly used, 
although other databases with a minimum of 2,000 alleles are also sufficient.  However, we 
encourage the use of a large dataset such as gnomAD, ExAC, or ESP.  
Since most RUNX1 variants are unique to probands or families,13 it was determined that 
the variant must be completely absent from all population databases in order to apply PM2. The 
MM-VCEP tested pilot PATH/LPATH variants with this rule, and validated this determination. 
The MM-VCEP further recommends that the mean coverage of exome and genome sequencing 
data for RUNX1 in the population databases used should be at least 20x. 
Criterion PS4 is based on the significantly higher prevalence of a variant in cases versus 
controls, which is considered strong evidence for pathogenicity. Ideally, published case-control 
studies are used as evidence. Given the rarity of FPD/AML, an existing case-control study for 
RUNX1 variants could not be identified. The original ACMG/AMP guideline states that odds ratio 
(OR), measuring an association between a genotype and phenotype, can be used for 
Mendelian diseases. Accordingly, in the absence of a published case-control study, the MM-
VCEP created a ‘quasi-case-control study’ with the estimated number of probands worldwide 
and the overall gnomAD population as the control cohort. In order to apply this code, the 
proband has to meet at least one of the RUNX1-phenotypic criteria (Table 2), and the variant 
has to be either absent from gnomAD or only present once. This code has a sliding weight scale 
to account for the number of unrelated probands who meet the RUNX1-phenotypic criteria. PS4 
is applied with ≥ 4 probands (OR 100.6), PS4_moderate with 2-3 probands (OR 50.3-75.5) and 
PS4_supporting with 1 proband (OR 25.1) (Table S1).  
BP2, supporting evidence for a benign code, can be applied in the context of autosomal 
dominant FPD/AML when the variant is found in trans with a known pathogenic variant. Since 
 14 
there is no evidence in the literature of probands with a homozygous pathogenic RUNX1 
variant, and lack of Runx1 is embryonically lethal in mice, the MM-VCEP recommends that BP2 
also be applied when a variant is found in a confirmed homozygous state in population 
databases or internal laboratories.43,44  
Segregation data (PP1_strong, PP1_moderate, PP1, BS4)  
Segregation with disease (PP1) is used as evidence for pathogenicity and with 
increasing number of meioses, a stronger level of evidence can be applied. The MM-VCEP 
adopted the approach taken by other ClinGen EPs,45–48 and supported by the SVI and others,49 
that additional meioses support higher levels of evidence. Thus, based on calculated logarithm 
of the odds (LOD) score thresholds of 0.9, 1.5, and 2.1, respectively, three or four meioses fulfill 
criteria for PP1, five or six meioses for PP1_moderate and seven or more meioses for 
PP1_strong. Of note, only individuals well documented as having a RUNX1 phenotype (Table 2) 
and a positive genotype or obligate carriers are included when counting segregations. The 
phenotype of those individuals should be well described. We waived the ACMG/AMP 
recommendation for demonstrating co-segregation in more than one family, given that many 
RUNX1 variants are unique to a single family13 and have not been reported in other unrelated 
families, which would severely affect the utility of segregation data. We acknowledge that by 
waiving this recommendation, there is a possibility of the identified variant being in a linkage 
disequilibrium with a truly causative variant.  
Lack of segregation in affected family members (BS4) can be used as a benign criterion 
when a RUNX1 variant is present and non-segregation with disease occurred in at least two or 
more informative meioses. BS4 should only be applied for genotype-positive, phenotype-
negative family members and there must be confidence that the family members do not meet 
any of our RUNX1-phenotypic criteria, taking into account ages of individuals.   
De novo occurrence (PS2_moderate, PS2_supporting, PM6, PM6_supporting)  
 De novo RUNX1 variants are rare, but have been reported in the literature.16–18  
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The two de novo criteria are applied when both maternity and paternity are confirmed (PS2) or 
assumed (PM6), and the variant has been assessed as de novo in a patient with the disease 
and no family history. The following specifications were added by our MM-VCEP: (1) No family 
history is defined by the absence of the FPD/AML specific phenotype in first- and/or second-
degree relatives, and (2) the proband must exhibit at least one phenotypic FPD/AML criterion 
(Table 2). PS2/PM6 were further specified using the SVI recommendation of a point-based 
scoring system to determine the level of strength. The FPD/AML phenotype is not highly 
specific, and there is substantial genetic heterogeneity - the same phenotype can be caused by 
other underlying germline conditions such as pathogenic variants in ANKRD2650 or ETV6.51 We 
thus concluded that due to the lack of a highly specific phenotype and the presence of genetic 
heterogeneity, the maximum allowable value is 1 point contributing to the overall score. Due to 
this restriction, these two criteria do not have a strong or very strong level of evidence. 
PS2_moderate is reached with a score of 1 point (two or more proven de novo occurrences) 
and PS2_supporting is utilized when reaching a score of 0.5 points (one proven de novo 
occurrence). Likewise, PM6_moderate is met when four assumed de novo occurrences are 
present (score of 1), and PM6_supporting is applicable with two to three assumed de novo 
cases (score of 0.5). Combining these two criteria (e.g. in the case of the same variant having 
both confirmed and assumed de novo evidence) is possible with the recognition that the 
maximum allowable value is still 1 point, which effectively leads to the application of one 
moderate or two supporting rules (Table S2).  
Computational and predictive data (PVS1, PVS1_strong, PVS1_moderate, PS1, 
PS1_moderate, PM1, PM1_supporting, PM4, PM4_supporting, PM5_strong, PM5, 
PM5_supporting, PP3, BP4, BP7) 
RUNX1 germline variants have been well described as being dominant-negative, loss-of-
function (LOF), or hypermorphic.13,31,52,53 Three major isoforms (A, B, C) are expressed by the 
use of two promoters and alternative splicing (Figure 1B). Expression of the short human 
 16 
RUNX1A isoform has been shown to favor expansion of the hematopoietic stem cell pool, 
whereas expression of the full length RUNX1B and RUNX1C isoforms, which only differ by 33 
amino acids (AA) at the N-terminus of isoform C (exons 2-3 in NM_001754.4), function to 
promote hematopoietic differentiation.54–61 The differential function and expression of these 
isoforms in hematopoietic tissue is not fully understood. The MM-VCEP recommends using 
RUNX1 isoform C as the default transcript (NM_001754.4), since this is the isoform used for 
annotation by most clinical laboratories. The MM-VCEP decision tree for SNVs/indels (Figure 2, 
Table S3) and CNVs (Figure S1) refined the PVS1 criterion across all LOF variant types 
previously reported for RUNX1 (nonsense, frameshift, canonical splice site variants and single- 
or multi-exon deletions) by using the SVI recommendations27 and gene-specific adjustments. 
We recommend down-grading the strength level from very strong to strong for C-terminal 
variants that are not predicted to undergo nonsense mediated decay (NMD) but affect the 
transactivation domain (TAD), inhibitory domain and/or the VWRPY motif (Figure 1).62,63 NMD is 
not predicted if the premature termination codon occurs in the 3’ most exon or within the 3’ most 
50 nucleotides of the penultimate exon.64,65 Deletions of exon 2-3, presumably only affecting 
RUNX1 isoform C, have been reported in four families (unpublished data,66) displaying a typical 
FPD/AML phenotype and segregation with disease. Although the functional effects of the exon 
2-3 deletions on isoform C and potential effects on isoforms A and B require further 
investigations, we recommend applying PVS1_moderate according to the PVS1 CNV decision 
tree (Figure S1). The ClinGen CNV interpretation working group is currently developing a 
systematic framework for the clinical interpretation of CNVs, which will then benefit the curation 
of RUNX1 CNVs in the future. 
 A variant affecting the same AA residue as a previously established pathogenic variant 
can either lead to the same AA change (PS1) or a different AA change (PM5). The MM-VCEP 
added the following recommendations for both rules: RNA data, or agreement in splicing 
predictors show no splicing effects, which was defined as Splice Site Finder (SSF) and 
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MaxEntScan (MES) predicting either an increase in the canonical splice site score or a 
decrease of the canonical splice site score by no more than 10% and no putative cryptic splice 
sites are created. In addition, the previously established PATH/LPATH variant must be asserted 
PATH/LPATH based on MM-VCEP rules for RUNX1 before this rule can be applied. A strength 
modification was established for PS1 (same AA as previously established pathogenic variant) 
and PS1_moderate (same AA as previously established likely pathogenic variant). Likewise, 
PM5_strong is applied when two or more different pathogenic missense changes have been 
detected previously at the same AA residue, PM5 is used when a different pathogenic missense 
change has been seen previously at the same residue, and PM5_supporting is utilized when 
one missense change at the same residue has previously been determined to be likely 
pathogenic.  
 For in-silico evaluation of missense variants, the MM-VCEP recommends using REVEL, 
a meta-predictor that combines 13 individual tools with high sensitivity and specificity and has 
recently demonstrated the highest performance compared to any individual tool or other 
ensemble methods.67,68 For splicing predictions, we recommend using the SSF and MES, both 
of which have been shown to predict splicing effects with high accuracy.69–71 PP3, defined as 
multiple lines of computational evidence supporting a deleterious effect, can be applied for 
missense variants with a REVEL score of >0.75. It can also be applied for missense or 
synonymous variants if the variant alters the last three bases of an exon preceding a splice 
donor site or the first three bases of an exon following a splice acceptor site69 and the predicted 
decrease in the score of the canonical splice site (measured by both MES and SSF) is at least 
75% regardless of the predicted creation/presence of a putative cryptic splice site. PP3 should 
be applied for intronic variants (in introns 4-8) located in reference to exons at positions +3 to +5 
for splice donor sites or -3 to -5 for splice acceptor sites69,72 for which the predicted decrease in 
the score of the canonical splice site is at least 75% (measured by both MES and SSF) 
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regardless of the predicted creation/presence of a putative cryptic splice site. PP3 cannot be 
used for canonical splice site variants.  
The benign criterion BP4 should be applied for missense variants if all of the following 
criteria apply: the variant’s REVEL score is < 0.15, SSF and MES predict either an increase in 
the canonical splice site score or a decrease of the canonical splice site score by no more than 
10%, and no putative cryptic splice sites are created. BP4 should also be applied for 
synonymous, intronic, and non-coding variants for which SSF and MES predict either an 
increase in the canonical splice site score or a decrease of the canonical splice site score by no 
more than 10%, and no putative cryptic splice sites are created. 
 The original PM1 code can be applied for variants affecting mutational hotspots and/or 
functional domains without benign variation. The Runt homology domain (RHD), spanning from 
AA 77-204, has been established as a highly conserved DNA binding domain without any 
benign variation in ClinVar. Thirteen somatic and/or germline mutational hotspots within the 
RHD have been identified: R107, K110, A134, R162, R166, S167, R169, G170, K194, T196, 
D198, R210, R204.12,20,73,74 The MM-VCEP recommends using PM1 for variants affecting these 
thirteen AA residues. For variants in other parts of the RHD for which germline variants have 
been previously reported (AA 105-204), a reduced strength-level (PM1_supporting) is 
recommended. For other residues within the RHD (AA 77-104), no germline RUNX1 pathogenic 
variants have been reported to date. In the future, the AA range under PM1_supporting may be 
expanded to other parts of the protein if more evidence emerges. Analogous to PM1, PM4 
(protein length changes due to in-frame deletions/insertions in a non-repeat region or stop-loss 
variants) is applied to in-frame deletions/insertions impacting the same thirteen AA residues 
(listed above) and, likewise, PM4_supporting can be utilized for in-frame deletions/insertions 
impacting at least one of the other parts of the RHD where germline variants have been 
previously reported (AA 105-204). 
 19 
 The MM-VCEP agreed to extend BP7 (synonymous variant with no splicing effect and 
position is not highly conserved) to apply to intronic/non-coding variants at or beyond positions 
+7/-21 for which SSF and MES predict either an increase in the canonical splice site score or a 
decrease of the canonical splice site score by no more than 10%, no putative cryptic splice sites 
are created and the position is not conserved, e.g. PhyloP score < 0.175 or the variant is the 
reference nucleotide in one primate and/or three mammal species.76 
Functional data (PS3, PS3_moderate, PS3_supporting, BS3, BS3_supporting) 
 The evolutionarily conserved 128 AA RHD, present in most of the RUNX1 isoforms 
(Figure 1B), is involved in DNA binding and heterodimerization with CBF. Heterodimerization 
of RUNX1 with CBF promotes DNA binding by stabilizing the interaction of the complex with 
the DNA. RUNX1 regulates the activity of several important hematopoietic genes, such as the 
granulocyte-macrophage colony-stimulating factor,77,78 T-cell receptor,79,80 myeloperoxidase,81,82 
and neutrophil elastase,82 by binding to a core sequence (TGTGGT) found in their promoters or 
enhancers.  
 Transactivation assays demonstrating altered transactivation compared to wild type are 
often performed as functional studies to evaluate the pathogenicity of a RUNX1 variant. 
Promoter sequences of M-CSFR, PF4, C-FMS and GZMB, containing consensus RUNX1 
binding sites TGTGGT have been used for this purpose.31,83–87  Data from secondary assays are 
frequently used to evaluate an altered function of mutant RUNX1. Electrophoretic mobility shift 
assays31,87–90 and yeast hybrid assays88,89 are performed to demonstrate decreased DNA 
binding affinity, and co-immunoprecipitation assays,85,90,91 fluorescence resonance energy 
transfer assays88 and affinity assays31 can demonstrate diminished heterodimerization ability of 
mutant RUNX1 with CBF. Abnormal cellular localization of mutant RUNX1 can be shown by 
immunofluorescence31,53,83 and cell-fractionation with Western blot.85,90 Sorted primary 
hematopoietic stem and progenitor cells can be used to demonstrate reduced colony-forming 
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potential,53,92 and xenotransplantation experiments may reveal abnormal function of mutant 
RUNX1 in vivo.53 
 The MM-VCEP defined the strong pathogenic code PS3 as the combination of reduced 
transactivation (<20% of wild type and/or reduced to levels similar to well-established 
pathogenic variants such as R201Q or R166Q) and data from a secondary assay that 
demonstrate altered function of mutant RUNX1. The transactivation assay should include wild 
type and known pathogenic controls as well as co-expression with CBFβ. PS3 can also be 
applied for evidence of very low or abnormal mRNA/protein expression of the variant allele as a 
functional consequence of a null variant or incorrect mRNA/protein products. The MM-VCEP 
further stipulates that PS3 cannot be applied if the variant meets PVS1. If the variant meets 
PVS1_strong and PS3, we recommend applying either PVS1_strong and PS3_moderate or 
upgrading PVS1_strong to PVS1 without applying PS3. PS3_moderate is applied when data 
from transactivation assays show reduced transactivation (<20% of wild type and/or reduced to 
levels similar to well-established pathogenic variants such as R201Q or R166Q) or two or more 
secondary assays demonstrating altered function. PS3_supporting can be applied for 
transactivation assays demonstrating enhanced transactivation (>115% of wild type) as has 
been shown previously for the hypermorphic RUNX1 mutant, S388X.52  
Likewise, the BS3 requirements (functional studies show no damaging effect on protein 
function) are a normal transactivation (80-115% of wild type) and data from a secondary assay 
that demonstrate normal function. BS3_supporting can be applied when there is evidence of 
normal transactivation (80-115% of wild type) while data from secondary assays are not 
required. 
Rules deemed not applicable 
Four rules of the pathogenic framework (PM3, PP2, PP4, PP5) and five rules of the 
benign framework (BS2, BP1, BP3, BP5, BP6) were deemed not applicable.  The reasoning 
behind the decision for each code is explained briefly below:  
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 Because the FPD/AML phenotype is associated with autosomal dominant transmission, 
PM3 (detected in trans with a pathogenic variant in a recessive gene) cannot be applied for 
FPD/AML. 
 The recommended cutoff for PP2 (missense variant in a gene with low rate of missense 
variants) is a constraint z score of  3.09,28 which was not met by RUNX1. 
The phenotype observed in FPD/AML is rather non-specific and can be caused by a 
number of other inherited predisposition syndromes, somatic variants, or environmental factors, 
which make the original ACMG/AMP rule PP4 for a highly specific phenotype not applicable to 
RUNX1. 
 Incomplete penetrance, an average age of onset of 33 years for hematologic 
malignancies,19–21 and the lack of sufficient clinical data to exclude a RUNX1-related phenotype 
render BS2 (observed in a healthy individual with full penetrance at an early age) not applicable.  
Both missense and truncating variants have been described as causative in FPD/AML, 
making BP1 (missense variant in a gene with primarily truncating variants) not applicable.  
Similarly, RUNX1 does not contain a repetitive region without known function used to 
apply BP3.  
BP5 can be applied when the variant is found in a case with an alternate molecular basis 
for disease. The MM-VCEP concluded that this rule is not applicable because in rare 
circumstances, a patient can carry variants in two genes predisposing to hematologic 
malignancies, as has been described in case-reports. In addition, variants in other genes 
presenting as low-penetrance risk factors, modifier genes, and/or somatic mutations in 
hematopoietic stem and progenitor cells may contribute to the clinical presentation and 
complicate the search for the causative variant.93,94 
 Following recommendations from the SVI, the MM-VCEP agreed not to use the two 
variant classifications from reputable sources evidence codes (PP5 and BP6) based on the 
published rationale.95 
 22 
Performance of the MM-VCEP specifications in pilot variant classification 
For pilot testing, 52 variants with a broad spectrum of ClinVar assertions (twelve 
BEN/LBEN, fourteen VUS, twenty PATH/LPATH, four CONF, and two variants with no ClinVar 
assertions) were selected. The MM-VCEP applied the RUNX1-modified ACMG/AMP criteria to 
all pilot variants. During testing, experts were able to provide feedback on the usability of the 
evidence codes, comment on the weight of certain lines of evidence and suggest further 
modifications of the rule. A list of all pilot variants, the ClinVar submitters’ variant classification, 
and the classifications made by our MM-VCEP are presented in Table S4. Figure 3 compares 
the original ClinVar classifications with our MM-VCEP classifications grouped by PATH/LPATH, 
BEN/LBEN, VUS and CONF variants. Of the fourteen VUS, two were upgraded into the LPATH 
category. Of the four CONF variants, one was upgraded to PATH and three were downgraded 
to LBEN. Two of eighteen variants previously listed as PATH/LPATH in ClinVar were 
downgraded to VUS after applying the RUNX1-specific codes. MM-VCEP members with 
knowledge of the criteria applied by the ClinVar submitters were able to corroborate the VUS 
classifications. A detailed schematic of the RUNX1 gene and the newly classified pilot variants 
is shown in Figure 1A. Overall, applying the RUNX1 specifications to the VUS/CONF variants 
resulted in a reduction in VUS/CONF classifications of 33%. All of the twelve variants that were 
submitted in ClinVar as BEN/LBEN remained in this category, with most LBEN variants being 
downgraded to BEN and only two remaining LBEN. An overview of the frequency of pathogenic 
and benign evidence codes applied is given in Figure S2. The test set received a final 
concordance of 92% with consensus ClinVar classifications (90% for the PATH/LPATH test set, 
86% with the VUS test set, and 100% for the BEN/LBEN test set).  
 
Discussion 
RUNX1 is commonly mutated in hematologic malignancies with high rates of somatic 
variants in MDS/AML.73,96 Tumor-based next-generation sequencing panels covering RUNX1 
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among other genes are implicated in the molecular diagnostic process of MDS/AML in most 
treatment centers. Some of these somatic RUNX1 variants are subsequently determined to be 
germline.97 In addition, recent achievements such as the inclusion of inherited hematologic 
malignancies into the revised WHO classification of myeloid neoplasms and acute leukemia15 
and a more standardized evaluation of the family history have raised awareness of these 
syndromes among physicians. This will increase the identification of patients with FPD/AML. 
Accurate RUNX1 variant curation is fundamental for the appropriate clinical care of these 
patients, especially when considering a related donor for hematopoietic stem cell 
transplantation. In addition, FPD/AML with thrombocytopenia may be misdiagnosed as immune 
thrombocytopenic purpura and the correlating dysmegakaryopoiesis in the bone marrow can be 
mistaken as an early-stage-MDS, underscoring the importance of adequate RUNX1 variant 
curation.98,99    
 Our curation of pilot variants demonstrated the impact of our proposed rules to improve 
variant classification, resulting in a reduction of VUS/CONF variants by 33%.  Further use of 
these rules should continue to reduce the number of VUS and lead to fewer number of variants 
with VUS/CONF assertion within ClinVar. Being able to reclassify a variant from VUS/CONF 
assertions has a significant impact on patient care as it provides patients and physicians with 
the definitive data to guide treatment decisions, including donor selection amongst matched 
relatives.  As we implement these RUNX1-specific rules, the variant annotation in ClinVar will 
contain a link to the specific version of the MM-VCEP RUNX1 evidence rules, a summary of the 
specific evidence codes used for that variant, and a link to the ClinGen evidence repository 
where all the evidence evaluated for that variant is found. Given these detailed expert reviewed 
curations, MM-VCEP curated variants will be submitted under a “three-star expert panel 
reviewed” FDA recognized designation. We expect that our RUNX1-specific rules will require 
further updating as additional data become available, or at a minimum every two years, and will 
address improved computational modeling, functional assays, and larger and more ethnically 
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diverse population databases. Per ClinGen policy, RUNX1 VUS and LPATH variants will be 
reassessed by the expert panel every two years and other variants may be re-curated if 
discrepancies in the variant classification or new evidence emerge over time.  At any time, a link 
to the most up-to-date recommendations of RUNX1 evidence codes can be found on the MM-
VCEP homepage [https://www.clinicalgenome.org/affiliation/50034]. Furthermore, ongoing 
general refinements to the ACMG/AMP guidelines made by the ClinGen SVI will need to be 
addressed, particularly for the curation of intragenic RUNX1 deletions and consensus rules for 
evaluation of splicing predictions. The next step of the MM-VCEP will be the curation of all 
current ClinVar deposited RUNX1 variants. Further work will extend this study to other genes 
causing inherited hematologic malignancies.  
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Tables 
 
Table 1- MM-VCEP ACMG/AMP specifications for RUNX1 variants. 
Table 2- FPD/AML phenotypic criteria.  
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Figure Legends 
 
Figure 1- Schematic of RUNX1 exonic distribution, protein isoforms and functional 
domain structure with all 52 pilot variants and their final MM-VCEP classification. A 
Isoform C with Runt homology domain (RHD), transactivation domain (TAD) and the VWRPY 
motif and location of all 49 single-nucleotide pilot variants with their final MM-VCEP 
classification. Pathogenic (PATH) and likely pathogenic (LPATH) variants are shown at the top, 
variants with unknown significance (VUS), likely benign (LBEN), and benign (BEN) variants are 
shown at the bottom. The exonic distribution of isoform C is displayed below. B Schematic of 
RUNX1 isoforms A, B, and C and their functional domains. Regions in gray are unique to one 
isoform. The three pilot copy number variants are shown at the bottom with the deletion of 
exons 2 and 3 exclusively affecting the N-terminal 33 amino acids of isoform C.   
 
Figure 2- PVS1 decision tree for SNVs/indels. Application of different levels of strength for 
PVS1 depending on the prediction of non-sense mediated decay (NMD), the location within a 
known critical protein domain and the expression of alternative isoforms.  
 
Figure 3- Comparison of ClinVar and MM-VCEP classifications. Fifty previously asserted 
and ClinVar deposited RUNX1 variants are shown on the x axis. Final MM-VCEP classifications 
are color-coded (see legend on the right). ClinVar variants with previous LPATH, CONF and 
VUS assertions were most often re-classified using MM-VCEP specified rules for RUNX1.    
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Table 1- MM-VCEP ACMG/AMP specifications for RUNX1 variants .
RUNX1  rule specifications
ACMG/AMP 
criteria code Original ACMG/AMP rule summary Specification Stand alone Very strong Strong Moderate Supporting Comments
PVS1 Null variant  in a gene where LOF is a known mechanism of disease.
gene-specific, 
strength na na
RUNX1 LOF variants are a common mechanism of disease in FPD/AML. Three 
major isoforms (A, B, C) are expressed by use of two promotors and alternative 
splicing. C-terminal variants not predicted to undergo NMD are classified as 
PVS1_strong, deletions of exons 2 and 3, presumably only affecting RUNX1 
isoform 1C,  meet PVS1_moderate.
PS1
Same AA change as a previously 
established pathogenic variant regardless 
of nucleotide change. 
strength na na
Same AA change as a previously established 
pathogenic variant regardless of nucleotide 
change. 
Same AA change as a previously established 
likely pathogenic variant regardless of 
nucleotide change. 
na
(1) RNA data or agreement in splicing predictors show no splicing effects (SSF 
and MES predict either increase in canonical splice site score or decrease of  
canonical splice score by no more than 10% and no putative splice site are 
created). (2) The previously established PATH/LPATH variant must be 
asserted pathogenic/likely pathogenic based on MM-VCEP rules for RUNX1 
before this rule can be applied
PS2
De novo  (maternity and paternity 
confirmed) in a patient with the disease 
and no family history.
disease-specific, 
strength na na na
≥ 2 proven de novo occurrences (maternity 
and paternity confirmed) in patients with the 
RUNX1- phenotype.
1 proven de novo occurrence (maternity and 
paternity confirmed) in a patient with the 
RUNX1- phenotype.
(1) No family history is defined as: absence of the variant and any of the 
RUNX1- phenotypic criteria in first- and/or second-degree relatives. (2) The 
proband must exhibit at least one phenotypic FPD/AML criterion. (3) The 
maximum allowable strength by combining PS2 and PM6 criteria is to apply 
one moderate or two supporting rules.
PS3
Well-established in vitro  or in vivo 
functional studies supportive of a 
damaging effect.
gene-specific, 
strength na na
Transactivation assays demonstrating altered 
transactivation (<20% of wt, and/or reduced to 
levels similar to well-established pathogenic 
variants such as R201Q or R166Q) AND data from 
a secondary assay demonstrating altered function. 
PS3 cannot be applied if the variant meets PVS1. If 
the variant meets criteria for PVS1_strong and 
PS3, we recommend either applying PVS1_strong 
and PS3_moderate or upgrading PVS1_strong 
to PVS1 without applying PS3.   
Transactivation assays demonstrating altered 
transactivation (<20% of wt, and/or reduced 
to levels similar to well-established 
pathogenic variants such as R201Q or 
R166Q) OR ≥ 2 secondary assays 
demonstrating altered function.
Transactivation assays demonstrating 
enhanced transactivation (>115% of wt).
(1) Transactivation assays should include wt and known pathogenic controls, as
well as co-expression with CBFβ. Promoter sequences of CSF1R (M-CSF-R), 
PF4, C-FMS and GZMB, containing consensus RUNX1 binding sites have been
used for transactivation assays. (2) The following secondary assays have been 
performed: EMSA and yeast hybrid assays (decreased DNA-binding affinity), 
co-IP, FRET and affinity assays (diminished heterodimerization ability with 
CBFβ), IF and WB with cell fractionation (abnormal cellular localization), colony 
forming assays (reduced colony-forming potential), xenotransplantation 
experiments (abnormal function of mutant RUNX1 in vivo ). (3) PS3 can also be 
applied for evidence of very low or abnormal mRNA/protein expression of the 
variant allele as a functional consequence of a null variant or incorrect 
mRNA/protein products
PS4
The prevalence of the variant in affected 
individuals is significantly increased 
compared to the prevalence in controls.
disease-specific, 
strength na na ≥ 4 probands meeting RUNX1 -phenotypic criteria.
2-3 probands meeting RUNX1 -phenotypic 
criteria.
1 proband meeting RUNX1 -phenotypic 
criteria.
The affected individual has to fit at least one of the RUNX1 -phenotypic criteria 
AND variant has to be either absent from gnomAD (overall population) or only 
present once. 
PM1
Located in a mutational hot spot and/or 
critical and well-established functional 
domain without benign variation.
gene-specific, 
strength na na na
Variant affecting one of the following 13 
hotspot residues: R107, K110, A134, R162, 
R166, S167, R169, G170, K194, T196, D198, 
R201, R204.
Variant affecting one of the other AA residues 
105-204 within the RHD. 
The RHD (AA 77-204) has been established as highly conserved DNA-binding
domain without any benign variation in ClinVar. No germline pathogenic 
variants have been reported in residues in the region (AA 77-104) to date. The 
AA range under PM1_supporting  may be expanded in the future to other parts 
of the protein if more evidence emerges
PM2 Absent from controls. general recommendation na na na Per original ACMG/AMP guidelines. na
Variant must be completely absent from all population databases.
The mean coverage of RUNX1  in the population database used should be at 
least 20x.
PM3 For recessive disorders, detected in trans with a pathogenic variant. na FPD/AML is inherited in an autosomal dominant manner. 
PM4
Protein length changes due to in-frame 
deletions/insertions in a non-repeat region 
or stop-loss variants. 
gene-specific, 
strength na na na
In-frame deletion/insertion impacting at least 
one of the 13 hotspot residues R107, K110, 
A134, R162, R166, S167, R169, G170, K194, 
T196, D198, R201, R204
Other in-frame deletion/insertion impacting 
residues 105-204 within the RHD. see PM1
PM5 
Missense change at AA residue where a 
different missense change determined to 
be pathogenic has been seen before.
strength na na
Missense change at the same residue where ≥ 2  
different missense changes have previoulsy been 
determined to be pathogenic. PM5_strong cannot 
be applied together with PM1. 
Missense change at the same residue where 
a different missense change has previously 
been determined to be pathogenic.
Missense change at the same residue where a 
different missense change has previously been
determined to be likely pathogenic.
see PS1
PM6
Assumed de novo (but without 
confirmation of maternity and paternity) in 
a patient with the disease and no family 
history.
disease-specific, 
strength na na na
≥ 4 assumed de novo occurrences (without 
confirmation of maternity and paternity) in 
patients with the RUNX1- phenotype.
2 or 3 assumed de novo occurrences (without 
confirmation of maternity and paternity) in 
patients with the RUNX1- phenotype.
see PS2
PP1 Co-segregation with disease in multiple affected family members.
disease-specific, 
strength na na
≥ 7 meioses observed within one or across multiple 
families. 
5 or 6 meioses observed within one or across 
multiple families.
3 or 4 meioses observed within one or across 
multiple families.
(1) Affected individuals show at least one of the RUNX1 -specific phenotypic 
criteria. (2) Only genotype and phenotype positive individuals and obligate 
carriers are counted. (3) Demonstration of co-segregation in multiple families is 
not required since many RUNX1  variants are unique and only occur in one 
family.
PP2
Missense variant in a gene that has a low 
rate of benign missense variation and 
where missense variants are a common 
mechanism of disease.
na Missense constraint z-score for RUNX1  is < 3.09.
PP3
Multiple lines of computational evidence 
support a deleterious effect on the gene or 
gene product.
general 
recommendation na na na na Per original ACMG/AMP guidelines. 
(1) PP3 should be applied for missense variants with a REVEL score of >0.75 
(2) PP3 should be applied for missense or synonymous variants if the variant 
alters the last three bases of an exon preceding a donor splice site or the first 
three bases of an exon following a splice acceptor site and the predicted 
decrease in the score of the canonical splice site (measured by both MES and 
SSF) is at least 75% regardless of the predicted creation/presence of a putative 
cryptic splice site. (3) PP3 should also be applied for intronic variants (in 
introns 4-8) located in reference to exons at positions +3 to +5 for splice donor 
sites or -3 to -5 for splice acceptor sites for which the predicted decrease in the 
score is at least 75% (measured by both MES and SSF) regardless of the 
predicted creation/presence of a putative cryptic splice site. (4) PP3 cannot be 
applied for canonical splice site variants. 
PP4 
Patient’s phenotype or family history is 
highly specific for a disease with a single 
genetic etiology. 
na FPD/AML does not exhibit a highly-specific phenotype and there is substantial genetic heterogeneity.
PP5
Reputable source recently reports variant 
as pathogenic, but the evidence is not 
available to the laboratory to perform an 
independent analysis. 
na According to SVI recommendations.
BA1 Allele frequency is >5% in ESP, 1000G, orExAC. disease-specific MAF ≥ 0.0015 (0.15%) na na na na
(1) The variant is present in any general continental population dataset with a
minimum number of 2,000 alleles and variant present in≥ 5 alleles. 
BS1 Allele frequency is greater than expected for disorder. disease-specific na na
MAF between 0.00015 (0.015%) and 0.0015 
(0.15%) na na
(1) The variant is present in any general continental population dataset with a 
minimum number of 2,000 alleles and variant present in ≥ 5 alleles.  (2) Variant 
can be classified as likely benign based on BS1 alone if there is no 
contradictory evidence supporting pathogenicity.
BS2
Observed in a healthy adult individual for a
recessive (homozygous), dominant 
(heterozygous), or X-linked (hemizygous) 
disorder, with full penetrance expected at 
an early age. 
na FPD/AML patients display incomplete penetrance and the average age of onset of hematologic malignancies is 33 years.
BS3
Well-established in vitro  or in vivo 
functional studies show no damaging 
effect on protein function or splicing.
gene-specific, 
strength na na
(1) Transactivation assays demonstrating normal 
transactivation (80-115% of wt) AND (2) data from 
a secondary assay demonstrating normal function.
na Transactivation assays demonstrating normal transactivation (80-115% of wt). see PS3 (1) and (2)
BS4 Lack of segregation in affected members of a family.
general 
recommendation na na Applied when seen in ≥ 2 informative meioses. na na
This code should only be applied for genotype-positive, phenotype-negative 
(with sufficient laboratory evidence) family members.
BP1
Missense variant in a gene for which 
primarily truncating variants are known to 
cause disease. 
na FDP/AML is caused by both pathogenic missense and truncating variants.
BP2
Observed in trans  with a pathogenic 
variant for a fully penetrant dominant 
gene/disorder or observed in cis  with a 
pathogenic variant in any inheritance 
pattern. 
general 
recommendation na na na na Per original ACMG/AMP guidelines. BP2 can also be applied if the variant is detected in a homozygous state. 
BP3 In frame-deletions/insertions in a repetitive region without a known function na RUNX1 does not contain a repetitive region without known function.
BP4
Multiple lines of computational evidence 
suggest no impact on gene or gene 
product.
general 
recommendation na na na na Per original ACMG/AMP guidelines.
BP4 should be applied for missense variants if all of the following apply: (1) 
REVEL score < 0.15, (2) SSF and MES predict either an increase in the 
canonical splice site score or a decrease of the canonical splice site score by 
no more than 10%, and (3) no putative cryptic splice sites are created. BP4 
should also be applied for synonymous, intronic and non-coding variants for 
which SSF and MES predict either an increase in the canonical splice site score
or a decrease of the canonical splice site score by no more than 10% and no 
putative cryptic splice sites are created.
BP5 Variant found in a case with an alternate molecular basis for disease. na
In rare circumstances, a patient can carry two variants in genes predisposing to 
hematologic malignancies.
BP6
Reputable source recently reports variants 
as benign, but the evidence is not 
available to the laboratory to perform an 
independent evaluation. 
na According to SVI recommendations.
BP7
A synonymous variant for which splicing 
prediction algorithms predict no impact to 
the splice consensus sequence nor the 
creation of a new splice site AND the 
nucleotide is not highly conserved. 
general 
recommendation na na na na
Per original ACMG/AMP guidelines. BP7 can 
not be applied in combination with PP3.
Also applicable to intronic/non-coding variants at or beyond positions +7/-21 for 
which (1) SSF and MES predict either an increase in the canonical splice site 
score or a decrease of the canonical splice site score by no more than 10% and 
no putative cryptic splice sites are created AND (2) evolutionary conservation 
prediction algorithms predict the site as not conserved (e.g. PhyloP score < 0.1 
or the variant is the reference nucleotide in one primate and/or three mammal 
species.).
`
Per modified RUNX1  PVS1 decision tree for SNVs, indels and CNVs and table of splicing effects.
Abbreviations: AA: Amino Acid, ACMG: American College of Medical Genetics, AMP: Association for Molecular Pathology, CNV: Copy Number Variant, EMSA: Electrophoretic Mobility Shift Assay, FPD/AML: Familial Platelet Disorder with predisposition to Acute Myeloid Leukemia, FRET: Fluorescence Resonance Energy Transfer, IF: 
Immunofluorescence, IP: Immunoprecipitation, LOF: Loss-Of-Function, MAF: Minor Allele Frequency, MES: MaxEntScan, MM-VCEP: Myeloid Malignancy Variant Curation Expert Panel, na: not applicable, NMD: Nonsense-Mediated Decay, RHD: Runt Homology Domain, SNV: Single-Nucleotide Variant, SSF: Splice Site Finder, SVI: ClinGen Sequence 
Variant Interpretation Working Group, WB: Western Blot, wt: wild type.
Table 1
Table 2- FPD/AML phenotypic criteria.
Feature Details Life-time risk
Thrombocytopenia Mild to moderate, normal platelet size and volume, absence of other causes for thrombocytopenia. in most patients
Platelet ultrastructural 
and/or functional defects
Includes platelet alpha or dense granule secretion defects and 
impaired platelet aggregation (particularly in response to 
collagen and epinephrine).
unknown
Hematologic malignancy
Most commonly AML or MDS, less frequently T-ALL. There 
are rare case-reports of patients with germline RUNX1 
mutations and mixed MPN/MDS such as CMML, as well as 
case-reports of patients with B-ALL, and hairy-cell leukemia.
~44%
Abbreviations: ALL: Acute Lymphoblastic Leukemia, AML: Acute Myeloid Leukemia, CMML: Chronic 
Myelomonocytic Leukemia, FPD/AML: Familial Platelet Disorder with predisposition to Acute Myeloid Leukemia, 
MDS: Myelodysplastic Syndrome, MPN: Myeloproliferative Syndrome. 
Table 2
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RUNX1 PVS1 decision tree for SNVs/Indels 
Figure 2
Figure 3
